Judges

ANZ can't call its former group chief risk officer — now a strategic advisor for Clayton Utz — to give evidence as it defends a whistleblower case by former trader Etienne Alexiou.

Former ANZ trader Etienne Alexiou has admitted during cross-examination that lewd messages sent to other bankers through Bloomberg’s messaging platform were inappropriate and could cause offence.

Jayco must spell out its claim that it explained the specific features of its recreational vehicles to customers, as part of its defence to an ACCC case over alleged misleading statements, a judge has said.

An entity associated with the director of defunct Sydney builder Quasar Constructions has failed to hand over details about its assets to liquidators, prompting further orders with a warning from the court.

In the first penalty to be handed down for breaches of the Privacy Act, pathology services provider Australian Clinical Labs has agreed to cop a $5.8 million fine over a 2022 data breach that compromised the personal information of 223,000 customers of its Medlab business.

Piper Alderman claims a judge erred in finding there was no evidence that an agreement between Maurice Blackburn and Phi Finney McDonald to cooperate in running an ad tech class action against Google was struck for an anti-competitive purpose.

A judge has signed of on a settlement struck by the liquidator for failed financial services firm Babcock & Brown, which will resolve all remaining and future shareholder disputes, which have beleaguered the liquidator for 12 years.

An appeals court has binned construction firm Shamrock's second bid to toss waste management firm Cleanaway’s $31 million claim for costs associated with cleanup of an Ipswich dump following a flood.

The builder of the Duke apartment complex in the Melbourne suburb of Collingwood has blocked the property developer from accessing a bank guarantee, with a judge finding there were serious issues to be tried over payments under their $8 million contract.

Abbey Animal Health has managed only a “pyrrhic victory" in a patent case against rival Virbac over an antiparasitic drug, and must withdraw its Levamox Duo product from the market, a court has found.